Who
Helen Torley
President and CEO
Company insider
Files Form 4 as: President and CEO, Halozyme Therapeutics; Director, Quest Diagnostics; Director, Relypsa; EVP, Chief Commercial Officer, Onyx Pharmaceuticals.
In numbers
- Trades disclosed
- 736
- Buys
- 1
- Sells
- 101
- Bought
- $446K
- Sold
- $137.8M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 29 Aug 2011
- Last trade
- 8 Oct 2026
- Last filed
- 8 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Oct 2026filed 8 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code M | $368K20,000 at $18.41 | filing |
| 8 Oct 2026filed 8 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $520K4,810 at $108.18 | filing |
| 8 Oct 2026filed 8 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $337K3,090 at $108.91 | filing |
| 8 Oct 2026filed 8 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.3M11,900 at $110.00 | filing |
| 8 Oct 2026filed 8 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $22K200 at $110.51 | filing |
| 8 Oct 2026filed 8 Oct 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | $368K20,000 at $18.41 | filing |
| 7 Oct 2026filed 8 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $23K200 at $113.69 | filing |
| 7 Oct 2026filed 8 Oct 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | $368K20,000 at $18.41 | filing |
| 7 Oct 2026filed 8 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code M | $368K20,000 at $18.41 | filing |
| 7 Oct 2026filed 8 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $955K8,600 at $111.03 | filing |
| 7 Oct 2026filed 8 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.2M10,300 at $111.84 | filing |
| 7 Oct 2026filed 8 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $102K900 at $112.78 | filing |
| 6 Oct 2026filed 8 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code M | $368K20,000 at $18.41 | filing |
| 6 Oct 2026filed 8 Oct 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | $368K20,000 at $18.41 | filing |
| 6 Oct 2026filed 8 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $248K2,300 at $107.90 | filing |
| 6 Oct 2026filed 8 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $656K6,000 at $109.33 | filing |
| 6 Oct 2026filed 8 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.1M9,920 at $109.89 | filing |
| 6 Oct 2026filed 8 Oct 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $197K1,780 at $110.81 | filing |
| 11 Sep 2026filed 11 Sep 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $485K4,508 at $107.55 | filing |
| 11 Sep 2026filed 11 Sep 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | $368K20,000 at $18.41 | filing |
The newest 500 lines are listed; the numbers count every line.
News
No headline names them, or the companies they trade most, lately.